Related Experiment Video
Updated: Jun 27, 2026

Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System
Published on: November 22, 2016
What we know and don't know about the bioeffects of nanoparticles: developing experimental approaches for safety
Mel E Stratmeyer1, Peter L Goering, Victoria M Hitchins
1Center for Devices and Radiological Health, Food and Drug Administration, WO64-4078, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA. melvin.stratmeyer@fda.hhs.gov
Abstract:
The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) regulates nano-based medical products and therefore is required to address the safety and biological effects of nano-scale materials used in these products. Both in vitro and in vivo toxicological research studies are being conducted at the FDA to help determine the risks versus benefits of these new products. This article will briefly summarize some of the initial research findings from FDA-CDRH studies using TiO(2), polystyrene, and silicon nanoparticles.
Related Concept Videos
Toxicity Testing in Animals
Bioavailability Study Design: Healthy Subjects Versus Patients
Measurement of Bioavailability: Pharmacodynamic Methods
Bioavailability Study Design: Single Versus Multiple Dose Studies
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

